HealthTab™ Roll Out on Track and Operations Cashflow Positive
VANCOUVER, British Columbia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “AVCR”) is pleased...
Clinical Trial
BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments
BURLINGTON, Mass. and JERUSALEM, Oct. 11, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
- BBP-398, an investigational SHP2 inhibitor, is a potentially optimal agent for use in combination therapies given its continuous, once-daily...
Syneos Health Expands Partnership with Datavant to Accelerate Delivery of New Therapies to Patients
Collaboration Streamlines Clinical Trial Tokenization, Further Empowers Medical Affairs, Market Access, HEOR and Commercial Analytics for ClientsMORRISVILLE, N.C., Oct. 11, 2022...
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data...
Headline results from Phase I clinical trial of ultra-rapid acting insulin candidate AT247 demonstrate significantly accelerated insulin absorption and early exposure compared to gold standard insulins NovoLog® and Fiasp®
Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) HEADLINE RESULTS FROM PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN CANDIDATE...
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis
Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7%...
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
MORRISVILLE, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,...
Supernus Provides Regulatory Update on SPN-830
ROCKVILLE, Md., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and...
scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree
Funds to be used to facilitate U.S. commercial launch of FUROSCIX®BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc....
Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week
SZN-043 preclinical data shows rapid, transient increases in hepatocyte proliferation and was well tolerated in non-clinical toxicology studiesSZN-1326 preclinical data...
Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive ProductSAN DIEGO, Oct. 10, 2022 (GLOBE NEWSWIRE)...
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent...
scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure
FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide Commercial launch planned in Q1 2023...
Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Clinical validation of PRAME...
Cytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis
Phase 3 Clinical Trial to Proceed to Second Interim Analysis Expected to Occur in 2023SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022...
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
First Genetically Modified (TALEN®-edited) Iovance TIL Therapy with Inactivated PD-1 Expression SAN CARLOS, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) --...
First Wave BioPharma Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360
Poster presentation indicates new microgranule formulation elicited desired delayed release profile, offering protection at acidic pH and rapid release under...
Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
DEVON, Pa., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer
PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing...